Innohep

(Tinzaparin)

ApprovedSmall molecule

Tinzaparin is used to prevent and treat blood clots, particularly in patients undergoing surgery or those with certain types of blood clots in the legs or lungs.[2] Innohep is currently approved and in use across 11 indications[4].[1]

Innohep is one of 250 small molecule programs targeting Malignant Epithelial Tumor of Ovary. It is currently in Approved.

Indications

Total Trials

Active Trials

249

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Malignant Epithelial Tumor of OvaryApproved

Deep Vein ThrombosisApproved

Colon AdenocarcinomaApproved

PneumoniaActive, not recruiting

Kidney FailureActive, not recruiting

Low Molecular Weight HeparinTerminated

Ovarian CancerRecruiting

COVID-19Active, not recruiting

ThrombocytopeniaRecruiting

Pulmonary EmbolismCompleted

Malignant Epithelial Tumor of OvaryApproved

Approved

Deep Vein ThrombosisApproved

Approved

Colon AdenocarcinomaApproved

Approved

PneumoniaPreclinical

Active, not recruiting

Kidney FailurePreclinical

Active, not recruiting

Low Molecular Weight HeparinPreclinical

Terminated

Ovarian CancerPhase 2

Recruiting

COVID-19Phase 3

Active, not recruiting

ThrombocytopeniaApproved

Recruiting

Pulmonary EmbolismApproved

Completed

Showing 10 of 11 indications

Competition

Competitive Landscape

317 competitors in COVID-19

#DrugCompanyPhaseTrials

Innohep

Jazz Pharmaceuticals

Approved

2 2

Aldactone

Pfizer

Preclinical

1 3

Nexavar

Bayer

Preclinical

1 4

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 5

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 6

Benadryl

PParkedale

Preclinical

1 7

Nitrostat

VViatris Specialty LLC

Preclinical

1 8

Low-Molecular-Weight Heparin

Daiichi Sankyo

Preclinical

3 9

Glucocorticoid

AbbVie

Preclinical

1 10

Singulair

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Ovarian Cancer

NCT05284552

Q1 2027

Post-ApprovalRecruiting

Thrombocytopenia

NCT05255003

Q3 2027

Post-ApprovalRecruiting

Preeclampsia

NCT07361679

Q3 2028

Phase 3Recruiting

Thrombosis

NCT06370273

Clinical

Trials by Indication[1]

Venous Thromboembolism3 trials

Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)

Completed· LEO Pharma logo

LEO Pharma··NCT03099031·420 enrolled

A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism

Unknown status·TThe University of Hong Kong·Phase 3·NCT03240120·99 enrolled

Venous Thromboembolism Prophylaxis Post Cesarean Section

Unknown status·KKing Saud University··NCT01321788·300 enrolled

Pregnancy2 trials

Can Low Molecular Weight Heparin During Pregnancy With Intrauterine Growth Restriction Increase Birth Weight?

Completed·UUniversity of Aarhus·Phase 4·NCT01390051·50 enrolled

Safety and Efficacy of Therapeutic Anticoagulation With Tinzaparin During Pregnancy Via Weight-based Dosing

Completed·UUniversity of Calgary·Phase 4·NCT00851864·13 enrolled

Venous thrombosis2 trials

Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities

Completed·—·Phase 3·NCT00628576·99 enrolled

Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis

Completed·HHospital Universitari de Bellvitge·Phase 4·NCT00689520·241 enrolled

COVID-192 trials

Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial

Active, not recruiting·UUniversity of Melbourne·Phase 3·NCT04483960·2,200 enrolled

Intensive Dose Tinzaparin in Hospitalized COVID-19 Patients

Unknown status·UUniversity Hospital of Patras··NCT05036824·300 enrolled

MPA1 trial

Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses

Completed·MMaisonneuve-Rosemont Hospital··NCT02719418·28 enrolled

16 more indications

Post-thrombotic Syndrome1 trial

Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome

Terminated·SSunnybrook Health Sciences Centre·Phase 4·NCT04794569·9 enrolled

Kidney Failure1 trial

Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure

Terminated·SSt. Joseph's Healthcare Hamilton·N/A·NCT00186745·148 enrolled

Anticoagulation1 trial

Use of Tinzaparin for Anticoagulation in Hemodialysis

Completed·CChristine Ribic·Phase 4·NCT01930396·191 enrolled

Low Molecular Weight Heparin1 trial

MesoHep II: Intraperitoneal Low Molecular Weight Heparin in Peritoneal Dialysis

Terminated·—·N/A·NCT00135863·36 enrolled

Pneumonia1 trial

Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID)

Completed·—·N/A·NCT04730856·311 enrolled

Deep Vein Thrombosis1 trial

Effect of Tinzaparin on Inflammatory Biomarkers During the Acute Phase of Deep Vein Thrombosis

Active, not recruiting·—·N/A·NCT04741464·9 enrolled

Preeclampsia1 trial

LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention

Recruiting·—·Phase 4·NCT07361679·100 enrolled

Ovarian Cancer1 trial

Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer

Recruiting·UUniversity Hospital, Linkoeping·Phase 2·NCT05284552·40 enrolled

Metastatic Colorectal Cancer1 trial

TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer

Completed·GGalician Research Group on Digestive Tumors·Phase 3·NCT05625932·232 enrolled

Thrombocytopenia1 trial

STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis

Recruiting·TTzu-Fei Wang·Phase 4·NCT05255003·50 enrolled

Colorectal Cancer1 trial

Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer

Completed·OOttawa Hospital Research Institute·Phase 3·NCT01455831·616 enrolled

Cesarean Section1 trial

The STOP CLOT Pilot Study: Study of Low Molecular Weight Heparin in High Risk Cesarean Section

Completed·OOttawa Hospital Research Institute·Phase 2/3·NCT00225108·30 enrolled

Pulmonary Embolism1 trial

Tinzaparin in the Treatment of the Acute Pulmonary Embolism

Completed·—·Phase 4·NCT00711308·102 enrolled

Colon Cancer1 trial

Thromboprophylaxis for Patients Undergoing Surgical Resection for Colon Cancer

Completed·OOttawa Hospital Research Institute·N/A·NCT00967148·18 enrolled

Anticoagulant1 trial

Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer

Completed·—·Phase 2·NCT02260414·19 enrolled

Thrombosis1 trial

Thromboprophylaxis in Lower Limb Immobilisation (TiLLI): a Multicentre Study Comprising Two Linked Open Label Phase III Randomised Controlled Trials Evaluating the Effectiveness and Cost Effectiveness of Different Methods of Pharmacological Prophylaxis for Patients With Temporary Lower Limb Immobilisation.

Recruiting·QQueen Mary University of London·Phase 3·NCT06370273·10,044 enrolled

Regulatory

FDA Approval Timeline[5]

Jul 14, 2000

INNOHEP

NDA NDA020484

Sources

References

[1]
ClinicalTrials.gov — 26 trial records for Tinzaparin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Innohep drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Tinzaparin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Tinzaparin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020484). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Jazz Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Jazz Pharmaceuticals

Innohep

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Q3 2028

Trials by Indication[1]

Venous Thromboembolism3 trials

Pregnancy2 trials

Venous thrombosis2 trials

COVID-192 trials

MPA1 trial

Post-thrombotic Syndrome1 trial

Kidney Failure1 trial

Anticoagulation1 trial

Low Molecular Weight Heparin1 trial

Pneumonia1 trial

Deep Vein Thrombosis1 trial

Preeclampsia1 trial

Ovarian Cancer1 trial

Metastatic Colorectal Cancer1 trial

Thrombocytopenia1 trial

Colorectal Cancer1 trial

Cesarean Section1 trial

Pulmonary Embolism1 trial

Colon Cancer1 trial

Anticoagulant1 trial

Thrombosis1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News